Benzazepine derivatives for the treatment of neurological and psychiatric disorders
AssigneeGlaxo Group Limited
InventorsMark Bamford, Thomas Heightman, David Wilson, Jason Witherington
Life of this patent
Estimating the term…
Loading patent…
AssigneeGlaxo Group Limited
InventorsMark Bamford, Thomas Heightman, David Wilson, Jason Witherington
Estimating the term…
The present invention relates to novel benzazepine derivatives of formula (I); wherein: R1 represents —C3-7 cycloalkyl optionally substituted by C1-3 alkyl; R2 represents -aryl, -heterocyclyl, heteroaryl, -aryl-X—C3-8 cycloalkyl, cycloalkyl, -aryl-X-aryl, -aryl-X-heteroaryl, -aryl-X-heterocyclyl, -heteroaryl-X—C3-8 cycloalkyl, -heteroaryl-X-aryl, -heteroaryl-X-heteroaryl, -heteroaryl-X-heterocyclyl, -heterocyclyl-X—C3-8 cyclooalkyl, -heterocyclyl-X-aryl, -heterocyclyl-X-heteroaryl or -heterocyclyl-X-heterocyclyl; X represents a bond, O, CO, —CH2O—, —COCH2—, —COCH2O—, —CONR2b—, —COCH2NR2bCO—, —CSNH—, SO2, —SO2C1-3 alkyl-, —SO2C2-3 alkenyl-, —COC2-3 alkenyl-, —CO—C(R2a)(R2b)— or —CO—C(R2a)(R2b)CH2—; having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.
1-9. (canceled)
A compound of formula (I), a pharmaceutically acceptable salt, or solvate thereof:
A method of treatment of neurological diseases which comprises administering to a host in need thereof an effective amount of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt or solvate thereof.
Dependencies are inferred from the claim text.